Literature DB >> 21375524

Initial features and outcome of cutaneous and non-cutaneous primary extranodal follicular lymphoma.

Carlos Fernández de Larrea1, Antonio Martínez-Pozo, Santiago Mercadal, Adriana García, Gonzalo Gutierrez-García, Alexandra Valera, Gabriela Ghita, Luis Colomo, Eukene Gainza, Neus Villamor, Benet Nomdedeu, Teresa Estrach, Emili Montserrat, Elias Campo, Armando López-Guillermo.   

Abstract

Follicular lymphoma (FL), a typically nodal disease, can arise in extranodal sites in about 10% of cases. The present study aimed to analyse the main differential features of patients with primary extranodal FL. Thirty-nine patients with primary extranodal FL were identified from a series of 354 patients with FL diagnosed at a single institution and their main clinicobiological features were analysed. Twenty patients (5·6%) had a primary extranodal non-cutaneous FL, and 19 (5·4%) a cutaneous FL. BCL2(+) and CD10(+) expression and BCL2/IGHJ@ rearrangement were less frequently observed in cutaneous FL. Absence of 'B'-symptoms, early stage, absence of bone marrow involvement and low-risk Follicular Lymphoma International Prognostic Index (FLIPI) were more frequent in extranodal FL. Five-year overall survival (OS) was 100%, 83% and 78% for cutaneous, non-cutaneous and nodal FL, respectively. When stage I patients were analysed separately, no differences were seen in terms of OS. In multivariate analysis, FLIPI was the most important variable to predict outcome. In conclusion, extranodal FLs, particularly cutaneous, have particular clinico-biological features, which differentiate them from nodal cases. Nevertheless, primary site of the disease is not the main issue to predict outcome.
© 2011 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21375524     DOI: 10.1111/j.1365-2141.2011.08596.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  7 in total

Review 1.  Follicular lymphoma: first-line treatment without chemotherapy for follicular lymphoma.

Authors:  Patrick M Reagan; Jonathan W Friedberg
Journal:  Curr Treat Options Oncol       Date:  2015-07

2.  A Rare Case of Malignant Lymphoma Occurred at Spinal Epidural Space: A Case Report.

Authors:  Hyun-Jun Cho; Jang-Bo Lee; Junseok W Hur; Sung-Won Jin; Tai-Hyoung Cho; Jung-Yul Park
Journal:  Korean J Spine       Date:  2015-09-30

Review 3.  Follicular lymphoma with leukemic phase at diagnosis: a series of seven cases and review of the literature.

Authors:  Brady E Beltran; Pilar Quiñones; Domingo Morales; Jose C Alva; Roberto N Miranda; Gary Lu; Bijal D Shah; Eduardo M Sotomayor; Jorge J Castillo
Journal:  Leuk Res       Date:  2013-06-20       Impact factor: 3.156

4.  Has the time to come leave the "watch-and-wait" strategy in newly diagnosed asymptomatic follicular lymphoma patients?

Authors:  Antonio Rueda; María Casanova; Maximino Redondo; Elisabeth Pérez-Ruiz; Angeles Medina-Pérez
Journal:  BMC Cancer       Date:  2012-05-31       Impact factor: 4.430

5.  Update on treatment of follicular non-Hodgkin's lymphoma: focus on potential of bortezomib.

Authors:  Danielle M Brander; Anne W Beaven
Journal:  Patient Prefer Adherence       Date:  2012-03-23       Impact factor: 2.711

Review 6.  Dural Follicular Lymphoma: Case Report and Literature Review.

Authors:  Ellery Altshuler; Raymond Richhart; Umar Iqbal; Joanna Chaffin
Journal:  J Investig Med High Impact Case Rep       Date:  2021 Jan-Dec

7.  Sites of extranodal involvement are prognostic in patients with stage 1 follicular lymphoma.

Authors:  Aditi Shastri; Murali Janakiram; Ioannis Mantzaris; Yiting Yu; Jaime S Londono; Amit K Verma; Stefan K Barta
Journal:  Oncotarget       Date:  2017-07-14
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.